Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

69 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Total loss of MHC class I is an independent indicator of good prognosis in breast cancer.
Madjd Z, Spendlove I, Pinder SE, Ellis IO, Durrant LG. Madjd Z, et al. Among authors: spendlove i. Int J Cancer. 2005 Nov 1;117(2):248-55. doi: 10.1002/ijc.21163. Int J Cancer. 2005. PMID: 15900607
Cancer vaccines.
Durrant LG, Spendlove I. Durrant LG, et al. Among authors: spendlove i. QJM. 1996 Sep;89(9):645-51. doi: 10.1093/qjmed/89.9.645. QJM. 1996. PMID: 8917739 Review. No abstract available.
Decay accelerating factor (CD55): a target for cancer vaccines?
Spendlove I, Li L, Carmichael J, Durrant LG. Spendlove I, et al. Cancer Res. 1999 May 15;59(10):2282-6. Cancer Res. 1999. PMID: 10344729
105Ad7 cancer vaccine stimulates anti-tumour helper and cytotoxic T-cell responses in colorectal cancer patients but repeated immunisations are required to maintain these responses.
Durrant LG, Buckley DJ, Robins RA, Spendlove I. Durrant LG, et al. Among authors: spendlove i. Int J Cancer. 2000 Jan 1;85(1):87-92. doi: 10.1002/(sici)1097-0215(20000101)85:1<87::aid-ijc16>3.0.co;2-k. Int J Cancer. 2000. PMID: 10585589 Clinical Trial.
CD55 is over-expressed in the tumour environment.
Li L, Spendlove I, Morgan J, Durrant LG. Li L, et al. Among authors: spendlove i. Br J Cancer. 2001 Jan 5;84(1):80-6. doi: 10.1054/bjoc.2000.1570. Br J Cancer. 2001. PMID: 11139317 Free PMC article.
Human anti-idiotypic antibodies can be good immunogens as they target FC receptors on antigen-presenting cells allowing efficient stimulation of both helper and cytotoxic T-cell responses.
Durrant LG, Parsons T, Moss R, Spendlove I, Carter G, Carr F. Durrant LG, et al. Among authors: spendlove i. Int J Cancer. 2001 May 1;92(3):414-20. doi: 10.1002/ijc.1194. Int J Cancer. 2001. PMID: 11291080
International conference: progress in vaccination against cancer (PIVAC) 2002, Nottingham, UK.
Rees RC, Robins RA, Pawelec G, Muller L, Li G, Spendlove I. Rees RC, et al. Among authors: spendlove i. Cancer Immunol Immunother. 2003 Jun;52(6):403-7. doi: 10.1007/s00262-002-0366-3. Epub 2003 Apr 9. Cancer Immunol Immunother. 2003. PMID: 12684847 No abstract available.
Enhanced expression of the complement regulatory protein CD55 predicts a poor prognosis in colorectal cancer patients.
Durrant LG, Chapman MA, Buckley DJ, Spendlove I, Robins RA, Armitage NC. Durrant LG, et al. Among authors: spendlove i. Cancer Immunol Immunother. 2003 Oct;52(10):638-42. doi: 10.1007/s00262-003-0402-y. Epub 2003 Jun 14. Cancer Immunol Immunother. 2003. PMID: 12811528
Cancer vaccines entering Phase III clinical trials.
Durrant LG, Spendlove I. Durrant LG, et al. Among authors: spendlove i. Expert Opin Emerg Drugs. 2003 Nov;8(2):489-500. doi: 10.1517/14728214.8.2.489. Expert Opin Emerg Drugs. 2003. PMID: 14662001 Review.
Comparison of the immune response to a self antigen after DNA immunisation of HLA*A201/H-2Kb and HHD transgenic mice.
Ramage JM, Metheringham R, Moss R, Spendlove I, Rees R, Durrant LG. Ramage JM, et al. Among authors: spendlove i. Vaccine. 2004 Apr 16;22(13-14):1728-31. doi: 10.1016/j.vaccine.2004.01.034. Vaccine. 2004. PMID: 15068856
69 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback